SCHEMBL935401

SCHEMBL935401

Nc1nccc(-c2ccccc2C(F)(F)F)n1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMO O15229 1/20 0.60
CDC7 O00311 1/20 0.58
CCNE1 P24864 1/20 0.58
CDK2 P24941 1/20 0.58
DBF4 Q9UBU7 1/20 0.58
AURKA O14965 1/20 0.51
HSP90AA1 P07900 1/20 0.51
PRKACA P17612 1/20 0.51
ADORA2A P29274 1/20 0.51
CYP1A2 P05177 3/20 0.50
CYP3A4 P08684 3/20 0.50
ALOX15 P16050 1/20 0.50
TSHR P16473 1/20 0.50
MAPK1 P28482 1/20 0.50
HIF1A Q16665 1/20 0.50
HSD17B10 Q99714 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
PTPN1 P18031 4/20 0.49
DYRK1A Q13627 3/20 0.48
GSK3B P49841 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27964563 0.83 CYP1A2 (0.69) KMOCYP1A2CYP3A4ALOX15TSHR
SCHEMBL1838571 0.81 CDK2 (0.57) CDC7CCNE1CDK2DBF4PRKACA
SCHEMBL3364843 0.80 KMO (0.60) KMOCDC7CCNE1CDK2DBF4
SCHEMBL25428915 0.80 KMO (0.60) KMOCYP1A2CYP3A4ALOX15TSHR
SCHEMBL30353577 0.77 FEN1 (0.57) CDC7CDK2DBF4AURKAHSP90AA1
SCHEMBL5140478 0.77 FEN1 (0.57) CDC7CDK2DBF4AURKAHSP90AA1
SCHEMBL11371479 0.77 KMO (0.50) KMOCDC7CCNE1CDK2DBF4
SCHEMBL30046927 0.77 HSP90AA1 (0.60) CDK2AURKAHSP90AA1PRKACAADORA2A
SCHEMBL18130895 0.77 HSP90AA1 (0.60) CDK2AURKAHSP90AA1PRKACAADORA2A
SCHEMBL18333 0.76 CTSK (0.56) KMOCYP1A2CYP3A4ALOX15TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112010844-A Preparation method and application of N- (pyrimidine-2-yl) coumarin-7-amine derivative as protein kinase inhibitor 中国药科大学 2020-12-01 CN disclosed
US-8946266-B2 Substituted triazole and imidazole derivatives as gamma secretase modulators Janssen Pharmaceuticals, Inc. (US) 2015-02-03 US disclosed
EP-2454239-B1 SUBSTITUTED TRIAZOLE AND IMIDAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS JANSSEN PHARMACEUTICALS INC (US) 2014-08-13 EP disclosed
US-20120135981-A1 NOVEL SUBSTITUTED TRIAZOLE AND IMIDAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS CELLZOME LIMITED (GB) 2012-05-31 US disclosed
EP-2454239-A1 SUBSTITUTED TRIAZOLE AND IMIDAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS Janssen Pharmaceuticals Inc. (US) 2012-05-23 EP disclosed
WO-2011006903-A1 SUBSTITUTED TRIAZOLE AND IMIDAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC (US) 2011-01-20 WO disclosed
WO-2010046780-A2 ANTI VIRAL COMPOUNDS INSTITUT PASTEUR KOREA (KR) 2010-04-29 WO disclosed
WO-2010046780-A2 ANTI VIRAL COMPOUNDS INSTITUT PASTEUR KOREA (KR) 2010-04-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120135981-A1 NOVEL SUBSTITUTED TRIAZOLE AND IMIDAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS BACE1, BACE2, APH1A KMO 2695/4885CDC7 3272/4885CCNE1 391/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.